Tumour heterogeneity and the implications of mutations on GBM pathology are seen at the genomic level when the WHO re-classification of GBM based on the mutational status of isocitrate dehydrogenase (IDH) (72) and recently completed a further re-classification to include one additional feature such as of loss chr 10 or gain chr 7, EGFR ampli, or TERT (73). This evidence concerns the gene EGFR and glioblastoma.